# Tivdak (tisotumab vedotin-tftv) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tisotumab-vedotin-tftv

> The FDA approved Tivdak (tisotumab vedotin-tftv), sponsored by PFIZER INC (PFE), on September 20, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Tivdak (tisotumab vedotin-tftv) |
| Codes |  |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### September 20, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761208 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210920, review_priority PRIORITY; sponsor_name SEAGEN; product TIVDAK (TISOTUMAB VEDOTIN-TFTV)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761208%22

### April 29, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761208 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20240429, review_priority PRIORITY; sponsor_name SEAGEN; product TIVDAK (TISOTUMAB VEDOTIN-TFTV)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761208%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tisotumab-vedotin-tftv.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tivdak (tisotumab vedotin-tftv) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tisotumab-vedotin-tftv

```bibtex
@misc{secapidev_pdufa_tisotumab_vedotin_tftv_20261116,
  title        = {Tivdak (tisotumab vedotin-tftv) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tisotumab-vedotin-tftv}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tisotumab_vedotin_tftv_20261116","title":"Tivdak (tisotumab vedotin-tftv) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tisotumab-vedotin-tftv","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
